Abstract:Abstract Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies.

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

Regulation of PD-L1 expression in the tumor microenvironment

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Anti-Tumor Potential of Post-Translational Modifications of PD-1

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Generation, secretion and degradation of cancer immunotherapy target PD-L1

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

Regulatory mechanisms of PD-1/PD-L1 in cancers